Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial demonstrated that combination therapy with metformin plus rosiglitazone provided superior durability of glycemic control compared with metformin alone, with significantly lower treatment failure rates (38.6 vs. 51.7%), and metformin plus lifestyle was intermediate. Herein we describe the temporal changes in measures of β-cell function and insulin sensitivity over a 4-year period among the three treatments. RESEARCH DESIGN AND METHODS: TODAY participants (699) were tested periodically with an oral glucose tolerance test to determine insulin sensitivity (1/fasting insulin [1/IF]), insulinogenic index (△I30/△G30) or C-peptide index (△C30/△G30), and β-cell function relative to insulin sensitivity (oral disposition index [oDI]). RESULTS: During the first 6 months, metformin plus rosiglitazone exhibited a significantly greater improvement in insulin sensitivity and oDI versus metformin alone and versus metformin plus lifestyle; these improvements were sustained over 48 months of TODAY. Irrespective of treatment, those who failed to maintain glycemic control had significantly lower β-cell function (∼50%), higher fasting glucose concentration, and higher HbA1c at randomization compared with those who did not fail. CONCLUSIONS: The beneficial change in insulin sensitivity and the resultant lower burden on β-cell function achieved in the first 6 months with metformin plus rosiglitazone appear to be responsible for its superior glycemic durability over metformin alone and metformin plus lifestyle. However, initial β-cell reserve and HbA1c at randomization are independent predictors of glycemic durability. Therefore, efforts to preserve β-cell function before significant loss occurs and to reduce HbA1c may be beneficial in the treatment of youth with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Baseline adjusted geometric mean ± SE asymmetric limits (obtained as exp[mean ± SE of log values]) of OGTT-derived measures of insulin sensitivity (1/IF) (A), insulinogenic index (△I30/△G30) (B), and oDI ([1/IF] × [△C30/△G30]) (C) in the three treatment groups over 48 months of follow-up in TODAY, analyzed using log-transformed values. The P value refers to the overall effect of treatment group assignment in the longitudinal models for the various parameters under question within the groups.](https://figures.cochat.ai/paper-figures/be1b067684cd4881bcf619e3acd41518/effects-of-metformin-metformin-plus-rosiglitazone-and-metformin-plus-lifestyle-figure-1.jpg)
![Figure 2 Baseline adjusted geometric mean ± SE asymmetric limits (obtained as exp[mean ± SE of log values]) of OGTT-derived measures by treatment failure with the three treatment groups combined, analyzed using log-transformed values. A: Insulin sensitivity (1/IF). B: Insulinogenic index (△I30/△G30). C: oDI ([1/IF] × [△C30/△G30]). The P value refers to the overall effect of failed vs. not failed group assignment in the longitudinal models for the various parameters under question within the two groups.](https://figures.cochat.ai/paper-figures/20b5098a6cb74952b4dc2dac4d181449/effects-of-metformin-metformin-plus-rosiglitazone-and-metformin-plus-lifestyle-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Affected young people have a more rapid deterioration in blood glucose levels, an attenuated response to diabetes medication, and more rapid development of diabetes complications (269 -273).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [272]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A 20-35 % decline in beta cell function annually in 10-19 year olds has been reported compared to the ~7% loss in older individuals with T2DM 23 .”
From Type 2 diabetes in adolescents and young adults (2018) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Once treated with metformin after progressing to T2D, youth show a greater rate of treatment failure than adults ( 52 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [52]
In the citing paper
“Early-onset T2DM is also associated with a more aggressive disease phenotype than later-onset T2DM, characterized by a faster β-cell decline (4), higher glycated hemoglobin (HbA1C), higher body mass index (BMI), a more adverse cardiometabolic risk factor profile (5), earlier insulin dependence (6) and a greater risk of both microvascular and macrovascular complications (4).”
From Living with early-onset type 2 diabetes in young adulthood: a narrative review of lived experience and implications for developmentally appropriate care (2026) · cites this paper as [4]
In the citing paper
“β-Cell dysfunction is associated with impaired glycemic control and a greater likelihood of treatment failure in both younger and older adults with T2DM [43,46].”
From Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions (2025) · cites this paper as [43]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 Diabetes
TODAY Study Group (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109333 · Cited by 971
Self-citationThe Importance of β-Cell Failure in the Development and Progression of Type 2 Diabetes
Kahn, S. E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7713 · Cited by 660
Copeland, K. C., Zeitler, P., Geffner, M., Guandalini, C., Higgins, J., Hirst, K., Kaufman, F. R., Linder, B., Marcovina, S., McGuigan, P., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1642 · Cited by 464
Effect of Metformin in Pediatric Patients With Type 2 Diabetes
Jones, K. L., Arslanian, S., Peterokova, V. A., Park, J.-S., & Tomlinson, M. J. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.89 · Cited by 392 · cited 1×
“Even though metformin was effective in the short-term over 16 weeks (2), it remained unknown whether this effect was durable until the results of the TODAY (Treatment Options for type 2 Diabetes in Adolescents andYouth) trial showed.”
BackgroundThe TODAY Study Group (2007) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00237.x · Cited by 260
Self-citationKahn, S. E., Lachin, J. M., Zinman, B., Haffner, S. M., Aftring, R. P., Paul, G., Kravitz, B. G., Herman, W. H., Viberti, G., Holman, R. R., et al. (2011) · Diabetes · doi:10.2337/db10-1392 · Cited by 249 · cited 5×
“The ADOPT (A Diabetes Outcome Progression Trial) study of drugnaive adults with type 2 diabetes showed that the insulinogenic index declined at a rate of ;7–11% per year (12).”
BackgroundMethodResultInfluentialHyperinsulinemia in African-American Children
Arslanian, S. A., Saad, R., Lewy, V., Danadian, K., & Janosky, J. (2002) · Diabetes · doi:10.2337/diabetes.51.10.3014 · Cited by 236 · cited 1×
“In addition, differences in insulin clearance in different racial groups (21,22) could confound the insulinogenic index data.”
BackgroundThe Rosiglitazone Story — Lessons from an FDA Advisory Committee Meeting
Rosen, C. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078167 · Cited by 207 · cited 1×
“However, TODAY was designed and initiated prior to the discovery of the adverse effects of rosiglitazone (26).”
BackgroundGungor, N., Bacha, F., Saad, R., Janosky, J., & Arslanian, S. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.638 · Cited by 186
Cited by
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
KANALEY, J. A., COLBERG, S. R., CORCORAN, M. H., MALIN, S. K., RODRIGUEZ, N. R., CRESPO, C. J., KIRWAN, J. P., & ZIERATH, J. R. (2022) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002800 · Cited by 931
“In a multicenter study in youth with T2D (the TODAY Study), metformin therapy managed glycemia in half of participants, and the addition of rosiglitazone, but not lifestyle changes including PA, was superior to metformin alone (126,127).”
Type 2 diabetes in adolescents and young adults
Lascar, N., Brown, J., Pattison, H., Barnett, A. H., Bailey, C. J., & Bellary, S. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30186-9 · Cited by 824
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Young-onset type 2 diabetes mellitus — implications for morbidity and mortality
Magliano, D. J., Sacre, J. W., Harding, J. L., Gregg, E. W., Zimmet, P. Z., & Shaw, J. E. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0334-z · Cited by 483
β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · Diabetes Care · doi:10.2337/dc14-0396 · Cited by 460
Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities
Nadeau, K. J., Anderson, B. J., Berg, E. G., Chiang, J. L., Chou, H., Copeland, K. C., Hannon, T. S., Huang, T. T.-K., Lynch, J. L., Powell, J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1066 · Cited by 381
Arslanian, S., Bacha, F., Grey, M., Marcus, M. D., White, N. H., & Zeitler, P. (2018) · Diabetes Care · doi:10.2337/dci18-0052 · Cited by 349
“Furthermore, type 2 diabetes appears to be more aggressive in youth than adults, with a faster rate of deterioration of b-cell function (76) and poorer response to glucose-lowering medications (104).”
BackgroundThe Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · Figshare · Cited by 337
β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes
Saisho, Y. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i1.109 · Cited by 263
Al-Saeed, A. H., Constantino, M. I., Molyneaux, L., D’Souza, M., Limacher-Gisler, F., Luo, C., Wu, T., Twigg, S. M., Yue, D. K., & Wong, J. (2016) · Diabetes Care · doi:10.2337/dc15-0991 · Cited by 250
“control and b-cell decline was observed (19).”
Ke, C., Narayan, K. M. V., Chan, J. C. N., Jha, P., & Shah, B. R. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00669-4 · Cited by 239
Current insights and emerging trends in early-onset type 2 diabetes
Misra, S., Ke, C., Srinivasan, S., Goyal, A., Nyriyenda, M. J., Florez, J. C., Khunti, K., Magliano, D. J., & Luk, A. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00225-5 · Cited by 222
β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1425 · Cited by 222
“rate of treatment failure than adults (52).”
ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth
Zeitler, P., Arslanian, S., Fu, J., Pinhas-Hamiel, O., Reinehr, T., Tandon, N., Urakami, T., Wong, J., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12719 · Cited by 221
Cardiometabolic risk in obese children
Chung, S. T., Onuzuruike, A. U., & Magge, S. N. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13602 · Cited by 213
Esser, N., Utzschneider, K. M., & Kahn, S. E. (2020) · Diabetologia · doi:10.1007/s00125-020-05245-x · Cited by 192
Viner, R., White, B., & Christie, D. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31371-5 · Cited by 192
Zhao, M., Song, L., Sun, L., Wang, M., Wang, C., Yao, S., Li, Y., Yun, C., Zhang, S., Sun, Y., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2375 · Cited by 186
The RISE Consortium, Nadeau, K. J., Hannon, T. S., Edelstein, S. L., Arslanian, S. A., Caprio, S., Leschek, E. W., Zeitler, P. S., Buchanan, T. A., Ehrmann, D. A., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0787 · Cited by 176
ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents
Shah, A. S., Zeitler, P. S., Wong, J., Pena, A. S., Wicklow, B., Arslanian, S., Chang, N., Fu, J., Dabadghao, P., Pinhas‐Hamiel, O., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13409 · Cited by 170
RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B., Ghosh, S., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 167
Premature Mortality and Comorbidities in Young-onset Diabetes: A 7-Year Prospective Analysis
Chan, J. C. N., Lau, E. S. H., Luk, A. O. Y., Cheung, K. K. T., Kong, A. P. S., Yu, L. W. L., Choi, K.-C., Chow, F. C. C., Ozaki, R., Brown, N., et al. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.03.018 · Cited by 164
“Moreover, patients who failed had a more rapid decline in beta-cell function compared to those who did not fail (17).”
BackgroundThe RISE Consortium, Ehrmann, D. A., Temple, K. A., Rue, A., Barengolts, E., Mokhlesi, B., Van Cauter, E., Sam, S., Miller, M. A., Kahn, S. E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0244 · Cited by 162
Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes
Arslanian, S. A., Hannon, T., Zeitler, P., Chao, L. C., Boucher-Berry, C., Barrientos-Pérez, M., Bismuth, E., Dib, S., Cho, J. I., & Cox, D. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204601 · Cited by 150
Early onset type 2 diabetes mellitus: an update
Strati, M., Moustaki, M., Psaltopoulou, T., Vryonidou, A., & Paschou, S. A. (2024) · Endocrine · doi:10.1007/s12020-024-03772-w · Cited by 148
“…yearly β -cell function deterioration in early-onset T2DM was reported to be 20 – 35% by The Multi-Ethnic Treatment Options for T2DM in Adolescents and Youth (TODAY) study of 699 youth and adolescents with T2DM (mean age 14 years, USA), much higher compared to 7% per year in later-onset T2DM [28].”
BackgroundThe changing face of diabetes in youth: lessons learned from studies of type 2 diabetes
Hannon, T. S., & Arslanian, S. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12939 · Cited by 137
Perkovic, V., Agarwal, R., Fioretto, P., Hemmelgarn, B. R., Levin, A., Thomas, M. C., Wanner, C., Kasiske, B. L., Wheeler, D. C., Groop, P.-H., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.010 · Cited by 136
The RISE Consortium, Ehrmann, D. A., Temple, K. A., Rue, A., Barengolts, E., Mokhlesi, B., Van Cauter, E., Sam, S., Miller, M. A., Kahn, S. E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0243 · Cited by 115
We Can Change the Natural History of Type 2 Diabetes
Phillips, L. S., Ratner, R. E., Buse, J. B., & Kahn, S. E. (2014) · Diabetes Care · doi:10.2337/dc14-0817 · Cited by 103
“In both the TODAY study and the DPP, starting treatment when A1C levels were lower (in TODAY) and/ or b-cell function was better (in both TODAY and DPP) was associated with improved outcomes (23,24,36).”
BackgroundMethodGLP‐1 agonists for obesity and type 2 diabetes in children: Systematic review and meta‐analysis
Chadda, K. R., Cheng, T. S., & Ong, K. K. (2021) · Obesity Reviews · doi:10.1111/obr.13177 · Cited by 103
Care of diabetes in children and adolescents: controversies, changes, and consensus
Cameron, F. J., & Wherrett, D. K. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60971-0 · Cited by 99
Youth-Onset Type 2 Diabetes Mellitus: Lessons Learned From the TODAY Study
Narasimhan, S., & Weinstock, R. S. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.01.009 · Cited by 95
Diagnosis, treatment and prevention of type 2 diabetes mellitus in children and adolescents
Serbis, A., Giapros, V. I., Kotanidou, E. P., Galli‐Τsinopoulou, A., & Siomou, E. C. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i4.344 · Cited by 129
The regulation of PKA signaling in obesity and in the maintenance of metabolic health
London, E., & Stratakis, C. A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108113 · Cited by 102
Saisho, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050744 · Cited by 112
Michaliszyn, S. F., Mari, A., Lee, S., Bacha, F., Tfayli, H., Farchoukh, L., Ferrannini, E., & Arslanian, S. (2014) · Diabetes · doi:10.2337/db13-1951 · Cited by 92
Once-Weekly Exenatide in Youth With Type 2 Diabetes
Tamborlane, W. V., Bishai, R., Geller, D., Shehadeh, N., Al-Abdulrazzaq, D., Vazquez, E. M., Karoly, E., Troja, T., Doehring, O., Carter, D., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2275 · Cited by 91
Age-related diseases as vicious cycles
Belikov, A. V. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2018.11.002 · Cited by 90
Complication characteristics between young-onset type 2 versus type 1 diabetes in a UK population
Song, S. H. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000044 · Cited by 89
Malik, F. S., Sauder, K. A., Isom, S., Reboussin, B. A., Dabelea, D., Lawrence, J. M., Roberts, A., Mayer-Davis, E. J., Marcovina, S., Dolan, L., et al. (2022) · Diabetes Care · doi:10.2337/dc21-0507 · Cited by 80
Arslanian, S. A., Kim, J. Y., Nasr, A., Bacha, F. F., Tfayli, H. M., Lee, S., & Toledo, F. G. S. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12562 · Cited by 82
Insulin Clearance in Health and Disease
Najjar, S. M., Caprio, S., & Gastaldelli, A. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031622-043133 · Cited by 72
Arterial stiffness precedes hypertension and metabolic risks in youth: a review
Agbaje, A. O. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003239 · Cited by 88
“In addition, recent randomized controlled trials, metformin monotherapy and/or lifestyle modification have been unsuccessful in treating young-onset type 2 diabetes, warranting further research on ways to reduce the risk in early life [63,64].”
BackgroundHIF-1α inhibitor PX-478 preserves pancreatic β cell function in diabetes
Ilegems, E., Bryzgalova, G., Correia, J. C., Yesildag, B., Berra, E., Ruas, J. L., Pereira, T., & Berggren, P. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.aba9112 · Cited by 78
Early-onset type 2 diabetes: the next major diabetes transition
Luk, A., Wild, S. H., Jones, S., Anjana, R. M., Hivert, M.-F., McCaffrey, J., Gregg, E. W., & Misra, S. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00830-x · Cited by 81
Correlates of Medication Adherence in the TODAY Cohort of Youth With Type 2 Diabetes
Katz, L. L., Anderson, B. J., McKay, S. V., Izquierdo, R., Casey, T. L., Higgins, L. A., Wauters, A., Hirst, K., Nadeau, K. J., & for the TODAY Study Group (2016) · Diabetes Care · doi:10.2337/dc15-2296 · Cited by 72
“is associated with faster deterioration in glycemic control (33) as well as insulin secretion (34).”
BackgroundBarrett, T. G., Jalaludin, M. Y., Turan, S., Hafez, M., Shehadeh, N., & Panel, O. B. O. T. N. N. P. T. 2. D. G. E. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12953 · Cited by 73
“Options for T2D in Adolescents and Youth (TODAY) study showed a yearly 20% to 35% decline in beta-cell function in the 699 young people with T2D over a 4-year follow-up period, dependent on treatment group (metformin therapy, metformin plus lifestyle changes, and metformin plus rosiglitazone).(18) In a smaller prospec…”
BackgroundResultZeitler, P., Hirst, K., Copeland, K. C., El ghormli, L., Levitt Katz, L., Levitsky, L. L., Linder, B., McGuigan, P., White, N. H., Wilfley, D., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0848 · Cited by 70
ISPAD Clinical Practice Consensus Guidelines 2024: Type 2 Diabetes in Children and Adolescents
SHAH, A. S., Pérez, M. B., CHANG, N. T., Fu, J., Hannon, T. S., Kelsey, M. M., Peña, A. S., Pinhas‐Hamiel, O., Urakami, T., Wicklow, B. A., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543033 · Cited by 100
Lin, B., Coleman, R. L., Bragg, F., Maddaloni, E., Holman, R. R., & Adler, A. I. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00242-0 · Cited by 72
Importance of Beta Cell Function for the Treatment of Type 2 Diabetes
Saisho, Y. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3030923 · Cited by 82
“Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial showed that lower beta cell function at baseline was associated with poorer glycemic control after four years in adolescent patients with T2DM who were treated with metformin or metformin plus rosiglitazone [16].”
BackgroundAddressing psychosocial health in the treatment and care of adolescents with obesity
Jebeile, H., Cardel, M. I., Kyle, T. K., & Jastreboff, A. M. (2021) · Obesity · doi:10.1002/oby.23194 · Cited by 83
“As an example, in the TODAY study, adolescents with obesity and type 2 diabetes were found to have an aggressive course of diabetes with early deterioration of beta- cell function (15), and with nearly half being unable to maintain glycemic control (16).”
MethodAgbaje, A. O., BARKER, A. R., Mitchell, G. F., & Tuomainen, T.-P. (2022) · Hypertension · doi:10.1161/hypertensionaha.121.18754 · Cited by 72
The Prevalence of Obesity Among Children With Type 2 Diabetes: A Systematic Review and Meta-analysis
Cioana, M., Deng, J., Nadarajah, A., Hou, M., Qiu, Y., Chen, S. S. J., Rivas, A., Banfield, L. E., Toor, P. P., Zhou, F., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.47186 · Cited by 92
Ke, C., Stukel, T. A., Shah, B. R., Lau, E., Ma, R. C., So, W.-Y., Kong, A. P., Chow, E., Chan, J. C. N., & Luk, A. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003316 · Cited by 57
Estimation of insulin sensitivity in children: methods, measures and controversies
Brown, R. J., & Yanovski, J. A. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12146 · Cited by 71
Diabetic kidney disease in children and adolescents
Afkarian, M. (2014) · Pediatric Nephrology · doi:10.1007/s00467-014-2796-5 · Cited by 71
Pinto, T. E., Gusso, S., Hofman, P. L., Derraik, J. G. B., Hornung, T., Cutfield, W. S., & Baldi, J. C. (2014) · Diabetes Care · doi:10.2337/dc13-2031 · Cited by 67
“It is therefore hypothesized that early interventions may prevent or delay changes in cardiac function and reduce the elevated risk of developing microvascular and macrovascular morbidity in adolescents with diabetes (21,23).”
BackgroundLifestyle Therapy for the Treatment of Youth with Type 2 Diabetes
McGavock, J., Dart, A. B., & Wicklow, B. A. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0568-z · Cited by 70
Pathophysiology and treatment of prediabetes and type 2 diabetes in youth
Bacha, F., Hannon, T. S., Tosur, M., Pike, J. M., Butler, A., Tommerdahl, K. L., & Zeitler, P. S. (2024) · Diabetes Care · doi:10.2337/dci24-0029 · Cited by 57
Understanding the drivers and consequences of early-onset type 2 diabetes
Lim, L.-L., Jones, S., Cikomola, J. C., Hivert, M.-F., & Misra, S. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01012-8 · Cited by 59
Chernausek, S. D., Arslanian, S. A., Caprio, S., Copeland, K. C., ghormli, L. K. E., Kelsey, M. M., Koontz, M. B., Orsi, C. M., & Wilfley, D. E. (2015) · Diabetes Care · doi:10.2337/dc15-1557 · Cited by 52
“insulin sensitivity, as the product of insulin sensitivity multiplied by the CPI (CPoDI = 1/IF 3 ΔC30/ΔG30) (15).”
MethodSafety and Tolerability of the Treatment of Youth-Onset Type 2 Diabetes
TODAY Study Group (2013) · Diabetes Care · doi:10.2337/dc12-2390 · Cited by 52
Self-citationGalderisi, A., Giannini, C., Weiss, R., Kim, G., Shabanova, V., Santoro, N., Pierpont, B., Savoye, M., & Caprio, S. (2018) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30235-9 · Cited by 49
“Ethnic differences in T2D prevalence (1) as well in the success of therapeutic interventions (8) have been partially attributed to social and economic barriers that prevent certain ethnic groups to be engaged in the pharmaceutical and lifestyle interventions.”
BackgroundInfluentialWong, J., Constantino, M., & Yue, D. K. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0566-1 · Cited by 53
Arslanian, S. A., ghormli, L. K. E., Kim, J. Y., Bacha, F. F., Chan, C. L., Ismail, H. M., Katz, L. E. L., Levitsky, L. L., Tryggestad, J. B., White, N. H., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1122 · Cited by 52
Self-citationMisra, S., Holman, N., Barron, E., Knighton, P., Warner, J., Kar, P., Young, B., & Valabhji, J. (2023) · Diabetic Medicine · doi:10.1111/dme.14940 · Cited by 46
Managing early-onset type 2 diabetes in the individual and at the population level
Misra, S., Khunti, K., Goyal, A., Gable, D., Armocida, B., Tandon, N., Sachdev, P., Wild, S. H., Hivert, M.-F., & Beran, D. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01067-0 · Cited by 47
Sam, S., Edelstein, S. L., Arslanian, S. A., Barengolts, E., Buchanan, T. A., Caprio, S., Ehrmann, D. A., Hannon, T. S., Tjaden, A. H., Kahn, S. E., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0027 · Cited by 50
Middleton, T. L., Constantino, M. I., Molyneaux, L., D'Souza, M., Twigg, S. M., Wu, T., Yue, D. K., Zoungas, S., & Wong, J. (2020) · Diabetic Medicine · doi:10.1111/dme.14238 · Cited by 44
Nambam, B., Silverstein, J. H., Cheng, P., Ruedy, K. J., Beck, R. W., Wadwa, R. P., KLINGENSMITH, G. J., Willi, S. M., Wood, J., Bacha, F. F., et al. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12377 · Cited by 44
Concepción, J., Chen, K., Saito, R., Gangoiti, J. A., Mendez, E., Nikita, M. E., Barshop, B. A., Natarajan, L., Sharma, K., & Kim, J. J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234970 · Cited by 42
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Chawla, R., Madhu, S. V., Makkar, B. M., Ghosh, S. K., Saboo, B., Kalra, S., & On behalf of RSSDI-ESI Consensus Group (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00819-2 · Cited by 57
Li, J., Chattopadhyay, K., Xu, M., Chen, Y., Hu, F., Chu, J., & Li, L. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019697 · Cited by 43
TODAY Study Group, Katz, L. E. L., White, N. H., ghormli, L. K. E., Chan, C. L., Copeland, K. C., Lipman, T. H., Marcus, M. D., & Zeitler, P. S. (2021) · Diabetes Care · doi:10.2337/dc21-1074 · Cited by 45
Self-citationArslanian, S. A., ghormli, L. K. E., Bacha, F. F., Caprio, S., Goland, R., Haymond, M. W., Levitsky, L. L., Nadeau, K. J., White, N. H., Willi, S. M., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0455 · Cited by 40
FDA approval of GLP-1 receptor agonist (liraglutide) for use in children
Bacha, F. F. (2019) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(19)30236-6 · Cited by 40
Baldi, J. C., Manning, P. J., Hofman, P. L., & Walker, R. J. (2013) · Diabetes Care · doi:10.2337/dc13-1426 · Cited by 39
Barrett, J. S., Bishai, R., Bucci‐Rechtweg, C., Cheung, A., Corriol‐Rohou, S., Haertter, S., James, A., Kovacs, S. J., Liu, J., Potempa, D., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1000 · Cited by 38
“significant independent predictors of loss of glycemic control.(65) Several previous studies, despite use of different primary endpoints and lack of head-to-head prospective evaluations, reported similar observations, suggesting that b-cell failure may be more”
ResultType 2 diabetes in prepubertal children
Astudillo, M., Tosur, M., Castillo, B., Rafaey, A., Siller, A. F., Nieto, J., Sisley, S. R., McKay, S. V., Nella, A. A., Balasubramanyam, A., et al. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13254 · Cited by 39
Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes
Shehadeh, N., Barrett, T. G., Galassetti, P. R., Karlsson, C., Monyak, J. T., Iqbal, N., & Tamborlane, W. V. (2023) · NEJM Evidence · doi:10.1056/evidoa2300210 · Cited by 45
Zhou, Y., Chen, Y., Tang, Y., Zhang, S., Zhuang, Z., & Ni, Q. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01673-0 · Cited by 49
“Blood glucose control is especially challenging in younger individuals [11], Hsieh et al. found that those diagnosed at a younger age had the poorest glycemic control, regardless of diabetes duration [12].”
Utzschneider, K. M., Tripputi, M. T., Kozedub, A., Barengolts, E., Caprio, S., Cree‐Green, M., Edelstein, S. L., ghormli, L. K. E., Hannon, T. S., Mather, K. J., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108948 · Cited by 39
Zhang, Y., Song, M., Cao, Y., Eliassen, A. H., Wolpin, B. M., Stampfer, M. J., Willett, W. C., Wu, K., Ng, K., Hu, F. B., et al. (2022) · Diabetes Care · doi:10.2337/dc22-1575 · Cited by 40
Amutha, A., Unnikrishnan, R., Anjana, R. M., Coimbatore Subramaniam Shanthi, R., Rajalakshmi, R., Venkatesan, U., Muthukumar, S., Routray, P., Kayalvizhi, S., Gupta, P. K., et al. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13033 · Cited by 41
“ties in achieving tight glycaemic control in youth with T2DM as shown in the TODAY study.(41) We found that duration of diabetes was the major risk factor for”
MethodSerbis, A., Giapros, V. I., Tsamis, K. I., Balomenou, F., Galli‐Τsinopoulou, A., & Siomou, E. C. (2023) · Nutrients · doi:10.3390/nu15092217 · Cited by 46
The TODAY Study: An NIH Perspective on Its Implications for Research
Linder, B. L., Fradkin, J. E., & Rodgers, G. P. (2013) · Diabetes Care · doi:10.2337/dc13-0707 · Cited by 34
Methods for Measuring Risk for Type 2 Diabetes in Youth: the Oral Glucose Tolerance Test (OGTT)
Chen, M. E., Aguirre, R. S., & Hannon, T. S. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1023-3 · Cited by 41
Chung, G. E., Cho, E. J., Yoon, J. W., Yoo, J., Chang, Y. W., Cho, Y., Park, S. H., Han, K., Shin, D. W., & Yu, S. J. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154866 · Cited by 35
Weight change in the management of youth‐onset type 2 diabetes: the TODAY clinical trial experience
Marcus, M. D., Wilfley, D. E., ghormli, L. K. E., Zeitler, P. S., Linder, B. L., Hirst, K., Ievers‐Landis, C. E., Buren, D. J. V., Walders‐Abramson, N., & For the TODAY Study Group (2016) · Pediatric Obesity · doi:10.1111/ijpo.12148 · Cited by 33
“A substantial number of TODAY participants were unable to maintain adequate glycemic control during the first 6months of the trial; these participants were characterized by lower β-cell reserve at randomization and did not benefit from any of the TODAY randomized treatments and were discontinued (2).”
BackgroundMethodInfluentialBariatric Surgery: A Potential Treatment for Type 2 Diabetes in Youth
SHAH, A. S., D’Alessio, D. A., Ford‐Adams, M., Desai, A. P., & Inge, T. H. (2016) · Diabetes Care · doi:10.2337/dc16-0067 · Cited by 38
“not progress to requiring insulin therapy (15).”
BackgroundDu, L., Wang, M., Kang, Y., Li, B., Guo, M., Cheng, Z., & Bi, C. (2017) · Oncotarget · doi:10.18632/oncotarget.14688 · Cited by 32
“As a commonly used oral anti-hyperglycaemic agent for type 2 diabetes mellitus (DM), metformin can improve insulin sensitivity by increasing peripheral glucose intake and utilization [1].”
BackgroundLiu, J., Liu, S., Gurung, R. L., Ang, K., Tang, W. E., Sum, C. F., Subramaniam, T., & Lim, S. C. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy211 · Cited by 36
Shankar, R. R., Zeitler, P., Deeb, A., Jalaludin, M. Y., Garcia, R., Newfield, R. S., Samoilova, Y., Rosario, C. A., Shehadeh, N., Saha, C. K., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13279 · Cited by 31
Jalaludin, M. Y., Deeb, A., Zeitler, P., Garcia, R., Newfield, R. S., Samoilova, Y., Rosario, C. A., Shehadeh, N., Saha, C. K., Zhang, Y., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13282 · Cited by 31
Metadata
- Authors
- TODAY Study Group
- Corresponding author
- TODAY Study Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-05-15
- Volume
- 36
- Issue
- 6
- Pages
- 1749-1757
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3661836
- OpenAlex
- W59232989
- Cited by
- 288
- References
- 25
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 30 · 2023: 25 · 2022: 37 · 2021: 28 · 2020: 27 · 2019: 16 · 2018: 23 · 2017: 12 · 2016: 12 · 2015: 16 · 2014: 18 · 2013: 8
- FWCI
- 14.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000130, UL1TR000005, UL1TR000448, UL1TR000439)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061239, U01DK061212, U01DK061254, U01DK061242, U01DK061230)
- National Center for Research Resources (M01RR000125, UL1RR024989, UL1RR025758, M01RR001066, UL1RR024153, UL1RR024134, M01RR000043, M01‐RR00043‐45, M01RR014467, M01RR000069, UL1RR024992, UL1RR024139, M01RR000084, M01RR000036, UL1RR025780)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- metformin, rosiglitazone, insulin sensitivity, beta-cell function, oral disposition index, insulinogenic index, treatment failure, beta-cell reserve
- MeSH terms
- Adolescent, Child, Diabetes Mellitus, Type 2, Drug Combinations, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Life Style, Male, Metformin, Thiazoles, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.